Amniotic Products Market Analysis and Forecast till 2031: By Type (Amniotic Membrane, Amniotic Suspensions), By Application (Wound Care, Orthopaedics, Ophthalmology, Other), By End User (Hospitals, Ambulatory Surgical Centres) and By Region

Amniotic Products Market Analysis and Forecast till 2031: By Type (Amniotic Membrane, Amniotic Suspensions), By Application (Wound Care, Orthopaedics, Ophthalmology, Other), By End User (Hospitals, Ambulatory Surgical Centres) and By Region

The amniotic products market was valued at $720 million in 2021 and it is anticipated to reach $1,680 million by 2031 at a CAGR of 8.8% during the forecast period (2022-2031).

Amniotic fluid is the protective liquid enclosed by the amniotic membrane that serves as a cushion for the growing fetus and facilitates the exchange of nutrients, water, and biochemical products between mother and fetus. Amniotic-derived products, comprising amniotic membrane and amniotic fluid products, are one subtype of orthobiologic that is being considered as a potential treatment option through augmentation of joint inflammation and healing. Amniotic membranes (AM) were initially employed for the treatment of skin disorders such as burns, ulcers, and wounds. The presence of a wide range of products of amniotic products used in the treatment of diseases is sustaining the need of healthcare facilities.

Market DriversGrowing incidence of burn injuries

The high incidence of the burn wound is likely to boost the growth of the market during the forecast period. According to WHO, an estimated 180,000 deaths every year are caused by burns-the high majority occur in low and middle-income economies. In India, over 1,000,000 people are moderately or severely burnt per year. Nearly 173,000 Bangladeshi children are moderately or severely burnt every year. Also, in Bangladesh, Colombia, Egypt, and Pakistan, 17% of children with burns have a temporary disability and 18% have a permanent disability.

Market OpportunityImplementation of the 21st Century Cures Act (US)

The 21st Century Cures Act was signed into law in the US in December 2016. Among other objectives, this new law has been enacted to advance regenerative medicine research and medical innovation. The Act includes various provisions that may impact the development and approval of several products in the upcoming years. Under this Act, a new “Regenerative Medicine Advanced Therapy” designation has been established, along with a fast-track approval pathway for new regenerative medicine products and therapies. The implementation of this Act can potentially result in the approval of new regenerative medicine products and therapies in the US, as well as stimulate R&D activities in the field of regenerative medicine.

Market RestraintsComplications and limitations associated with the use of amniotic membranes

Amniotic membranes are not to be used comprehensively since there could be an occasional risk of complications. The patient or the recipient of an amniotic membrane could transmit bacterial, viral, or fungal infections if the donors are not adequately screened for communicable diseases. Other risks to the patient/recipient may also occur if the membrane is not processed under sterile conditions, or if the membrane is inappropriately stored. Incidence rates of 1.6% to 8.0% have been reported post amniotic membrane transplantation, with gram-positive isolates being reported most frequently. Moreover, premature degradation of an amniotic membrane and cheese wiring may further lead to frequent and repetitive transplantations, which in itself is a risk.

Impact of COVID-19 on Amniotic Products Market

The COVID-19 outbreak negatively impacted the amniotic product market in 2020 owing to nationwide lockdowns, denied wound care services, and cancelled or postponed elective surgeries. Elective surgeries were being denied (cancelled/postponed) to reserve or redirect the available limited capacities and resources (such as hospital beds and patient care professionals) towards COVID-19 patient care. Adding to that, various countries had imposed lockdowns and curfews to curb the increasing number of COVID-19 cases. Owing to these lockdowns, patients were not able to visit hospitals, OPDs, or clinics. This temporary denial of non-emergent healthcare services is expected to limit the growth of the amniotic product market. However, the demand for amniotic products is expected to rise in the coming years.

Market Segmental Analysis

The amniotic products market is segmented into type, application, and end user.

Global Amniotic Products Market by Type

The various types of amniotic products comprised in the global amniotic products market are amniotic membranes and amniotic suspensions. The amniotic membrane segment is also sub-segmented into cryopreserved amniotic membranes and dehydrated amniotic membranes.

The amniotic membrane segment is likely to dominate the market. The key factors such as more effectiveness with compare to amniotic suspension is likely to propel the market growth.

Global Amniotic Products Market by Application

By application, the global amniotic product market is segmented into wound care, orthopedics, ophthalmology, and others.

The wound care segment is likely to dominate the market. The key factors such as the growing incidence of ulcers, traumatic and surgical wounds, and burns and the need for advanced technologies for the treatment is likely to boost the growth of the market.

Global Amniotic Products Market by End User

By end-user, the global amniotic products is bifurcated into hospitals, clinics, home care, research institutes, academic, and others.

The hospitals segment is likely to dominate the market. The key factors such as the use of amniotic products for ocular use or for using them in tendon and ligament repair are mostly procured in the hospitals coupled with reimbursement policies of this product is easily attained in hospitals are propelling the growth of the market.

Geographical Analysis of Global Amniotic Products Market

The global amniotic products market is studied for key countries of the regions such as North America, Europe, Asia Pacific, and the Rest of the World.

North America is likely to dominate the market during the forecast period. The key factors such as the high prevalence of target diseases coupled with increasing geriatric populations, rising awareness about advanced treatment options, and the strong presence of key market players in the regions are boosting the growth of the market in the region.

Market Players of Global Amniotic Products MarketKey Developments in Global Amniotic Products Market

• June 2021: Mimedx Group, Inc. announced successfully regulatory approval by the Japanese Ministry of Health, Labour and Welfare to market EPIFIX in Japan.
• May 2021: Smith and Nephew announced new evidence to be presented by the Advanced Wound Management franchise and the recently acquired Osiris Therapeutics, Inc. at the symposium on Advanced Wound Care (SAWC) and Wound Healing Society Spring (WHS) conference.
• January 2021: Integra Life Sciences completed the acquisition of ACell, Inc.
• January 2021: Organogenesis Holdings Inc. announced that the U.S. Food and Drug Administration (FDA) has granted ReNU, a cryopreserved amniotic suspension allograft for the management of symptoms associated with knee osteoarthritis (OA), RMAT designation.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.